Thales Introduces S3NS in Partnership With Google Cloud and Unveils Its Offering in a First Step Towards the French Trusted Cloud Label
30.6.2022 15:20:00 EEST | Business Wire | Press release
Thales announced today the creation of S3NS, a French company designed to offer public and private organizations in France the power of Google Cloud, fully compliant with France's “Trusted Cloud” label, in partnership with Google Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005160/en/
(Graphic: Thales)
The new company, majority owned and controlled by Thales, is under French law and follows the October 2021 partnership announcement between Thales and Google Cloud to jointly develop a locally-compliant Trusted Cloud offering. Thales and Google Cloud are committed to helping companies and public institutions to innovate and accelerate their digital transformation in ways that afford autonomy, compliant sovereignty, and the greatest possible benefits for their customers and users.
Meeting the French “Trusted Cloud”
S3NS will offer from the second half of 2024 its “trusted cloud” offering that will ultimately combine full performance, services and applications of Google Cloud technology while allowing protection against extraterritorial foreign laws and in compliance with the requirements of the “Trusted Cloud” label of France’s Information Systems Security Agency (ANSSI) in the frame of the French State strategy. S3NS will directly operate three data centers to ensure data and workload localisation in France. Both data center availability and engineering assistance will be available this year already and the recruitment of engineers who will operate the “Trusted Cloud” will begin.
A first milestone with an offering already available
S3NS' first offering is "Local control with S3NS", which will offer Google Cloud customers in France continued high public cloud performance, with added capabilities to localize clients’ data in France or in Europe, as needed or preferred. Customers will be able to restrict data access for administrative service and technical support solely to European Union locations. Cryptographic control of data access can be achieved with external encryption key management from S3NS. This first offering brings compliance with additional automation to simplify operations, along with additional auditability and transparency to increase customer confidence in cloud operations.
Committing partners already
To best support customers in this transition to the “Trusted Cloud”, S3NS is finalizing specific partnership agreements with various players in France's growing digital ecosystem. Partners will be able to support S3NS customers in their cloud and digital sovereignty strategy, as they migrate and operate their workloads and applications securely, with the help of S3NS’ and other managed services.
“The S3NS offering is the best of both worlds: the agility and wide range of services of a cloud hyperscaler combined with the security and data protection of a cybersecurity leader. This step marks the beginning of a technological and industrial adventure which will engage all the French economic players attached to a trusted solution. As a leader in critical information systems, Thales is once again demonstrating its ability to be a driving force in disruptive technologies.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems at Thales.
“The creation of S3NS, progress on the definition of our Trusted Cloud offering and the availability of our 'Local controls with S3NS' is the result of many months of collaboration between Thales and the Google Cloud teams. This is a first step and a first milestone this year, before our future solution in compliance with the French 'Trusted Cloud' criteria, which we are working on in parallel. Our objective is to be the first to make such an offering available for certification and based on hyperscale cloud technology. 'Local Controls with S3NS' enables our customers to start their journey to the trusted cloud now.” Cyprien Falque, Managing director of S3NS.
“We are very proud to support our partner Thales and its subsidiary S3NS and its first offering in the French market. This collaboration between our teams reflects on the one hand an understanding of the expectations related to digital sovereignty, and on the other hand a real technological trajectory. We confirm the commitments made together in 2021 and will continue to support digital transformation with offers that combine security and sovereignty, without compromising on performance.” Thomas Kurian, CEO at Google Cloud.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021 the Group generated sales of €16.2 billion.
PLEASE VISIT
https://www.linkedin.com/company/s3nscloud/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005160/en/
Contact information
Press
Thales, Media Relations
Security
Marion Bonnet
marion.bonnet@thalesgroup.com
+33(0)660384892
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
